Structural studies of matrix metalloproteinases

Journal of Molecular Medicine

Volumn 78, Issue 5, 2000, Pages 261-268

  Borkakoti, Neera ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Arthritis; Collagenase; Inhibitors; Matrix metalloproteinases; Molecular structural analyses

Indexed keywords

CALCIUM; COLLAGENASE; COLLAGENASE INHIBITOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ZINC;

ALZHEIMER DISEASE; ARTHRITIS; CHEMICAL STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; LIGAND BINDING; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 0033931053     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000113     Document Type: Review

References (64)

1. 1. Woessner JF (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145-2154
2. 2. Birkedal-Hansen H (1995) Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7:728-735
3. 3. Murphy GJ, Murphy G, Reynolds JJ (1991) The origin of matrix metalloproteinases and their familial relationships. FEBS Lett 89:4-7
4. 4. Pendas AM, Knauper V, Puente XS, Llano E, Mattei MG, Apte S, Murphy G, Lopez Otin C (1997) Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 272:4281-4286
5. 5. Birkedal-Hansen H, Moore WGL, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA (1993) Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4:197-250
6. 6. Goldring MB (1993) Degradation of articular cartilage in culture: regulatory factors. In: Woessner JF, Howell DS (eds) Joint cartilage degradation. Dekker, New York, pp 281-346
7. 7. Willenbrock F, Murphy G (1994) Structure-function relationships in the tissue inhibitors of metalloproteinases. Am J Respir Crit Care Med 150:5165-5170
8. 8. Murphy G, Willenbrock F (1995) Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 248:496-510
9. 9. Springman EB, Angelton EL, Birkedal-Hansen H, Van Wart H (1990) Multiple modes of activation of latent fibroblast collagenase-evidence for the role of a cys-73 active site zinc complex in latency and a "cysteine switch" mechanism. for activation. Proc Natl Acad Sci USA 87:364-368
10. 10. Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, Schneider G, Tryggvason K (1999) Structure of human promatrix metalloproteinase-2: activation mechanism revealed. Science 284:1667-1670
11. 11. Peress N, Perillo E, Zucker S (1995) Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J Neuropathol Exp Neurol 54:16-22
12. 12. Stetler-Stevenson WG, Hewitt R, Corcoran M (1996) Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 7:147-154
13. 13. Steinman L (1996) Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85:299-302
14. 14. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ (1996) Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 39:1576-1587
15. 15. Cawston T (1998) Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol Med Today 130-137
16. 16. Hardingham TE, Fosang AJ, Dudhia J (1992) Aggrecan-the chondroitin sulfate keratin sulfate proteoglycan from cartilage. In Kuettner K (ed) Articular cartilage and osteoarthritis. Raven, New York, pp 5-20
17. 17. Hardingham TE, Fosang AJ (1992) Proteoglycans: many forms and functions. FASEB J 6:861-870
18. 18. Prockop DJ, Kivirikko KI (1995) Collagens: molecular biology, diseases and potentials for therapy. Annu Rev Biochem 64:403-434
19. 19. Netzel-Arnett S, Mallya SK, Nagase H, Birkedal-Hansen H, Van Wart HE (1991) Sequence specificities of fibroblast and neutrophil collagenases. J Biol Chem 266:6747-6755
20. 20. Johnson WH, Roberts NA, Borkakoti N (1987) Collagenase inhibitors: their design and potential therapeutic use. J Enzyme Inhib 2:1-22
21. 21. Clark IM, Powell LK, Hazelman BL, Cawston TE (1993) The measurement of collagenase, TIMP and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 36:372-379
22. 22. Nagase H (1996) Matrix metalloproteinases. In: Hooper NM (Ed) Zinc metalloproteases in health and disease. Taylor and Francis, London pp 153-204
23. 23. Shingleton WD, Hodges DJ, Brick P, Cawston TE (1996) Collagenases: a key enzyme in collagen turnover. Biochem Cell Biol 74:759-775
24. 24. Borkakoti N (1999) The structural basis of matrix metalloproteinase inhibition. Curr Opin Drug Discov 2:449-462
25. 25. Borkakoti N, Winkler FK, Williams DH, D'Arcy A, Broadhurst MJ, Brown PA, Johnson WH, Murray EJ (1994) Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat Struct Biol 1:106-110
26. 26. Lovejoy B, Cleasby A, Hassell AM, Longley K, Luther MA, Weigl D, McGeehan G, McElroy AB, Drewry D, Lambert MH (1994) Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 263:375-377
27. 27. Lovejoy B, Hassell AM, Luther MA, Weigl D, Jordan SR (1994) Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. Biochemistry 33:8207-8217
28. 28. Lovejoy B, Welch AR, Carr S, Luong C, Broka C, Hendricks RT, Campbell JA, Walker KA, Martin R, Van Wart H, Browner MF (1999) Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 6:217-221
29. 29. Reiter LA, Rizzi JP, Pandit J, Lasut MJ, McGahee SM, Parikh VD, Blake JF, Danley DE, Laird ER, Lopez-Anaya A, Lopresti-Morrow LL, Mansour MN, Martinelli GJ, Mitchell PG, Owens BS, Pauly TA, Reeves LM, Schulte GK, Yocum SA (1999) Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket. Bioorg Med Chem Lett 9:127-132
30. 30. Bode W, Reinemer P, Huber R, Kleine T, Schnierer S, Tschesche H (1994) The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J 13:1263-1269
31. 31. Grams F, Reinemer P, Powers JC, Kleine T, Pieper M, Tschesche H, Huber R, Bode W (1995) X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design. Eur J Biochem 228:830-841
32. 32. Brandstetter H, Engh RA, Von Roedern EG, Moroder L, Huber R, Bode W, Grams F (1998) Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. A new binding mode explains apparently anomalous data. Protein Sci 7:1303-1309
33. 33. Moy FJ, Pisano MR, Chanda PK, Urbano C, Killar LM, Sung ML, Powers R (1997) Assignments, secondary structure and dynamics of the inhibitor-free catalytic fragment of human fibroblast collagenase. J Biomol NMR 10:9-19
34. 34. Borkakoti N (1998) Matrix metalloproteases: variations on a theme. Prog Biophys Mol Biol 70:73-94
35. 35. Gomis-Ruth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov GP, Bartunik H, Bode W (1997) Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389:77-81
36. 36. Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, Tschesche H, Maskos K (1998) Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 17:5238-5248
37. 37. Nagase H, Fields GB (1996) Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers 40:399-416
38. 38. Bottomley KM, Johnson WH, Walter DS (1998) Matrix metalloproteinase inhibitors in athritis. J Enzyme Inhib 13:79-101
39. 39. Broadhurst MJ, Brown PA, Lawton G, Ballantyne N, Borkakoti N, Bottomley K, Cooper MI, Eatherton AJ, Kilford IR, Malsher PJ, Nixon JS, Lewis EJ, Sutton BM, Johnson WH (1997) Design and synthesis of the cartilage protective agent (CPA, Ro32-3555). Bioorg Med Chem Lett 7:2299-2302
40. 40. Bode W, Reinemer P, Huber R, Kleine T, Schnierer S, Tschesche H (1994) The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J 13:1263-1269
41. 41. Esser CK, Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, Kopka IE, Lanza TJ, Levorse DA, MacCoss M, Owens KA, Ponpipom MM, Simeone JP, Harrison RK, Niedzwiecki L, Becker JW, Marcy AI, Axel MG, Christen AJ, McDonnell J, Moore VL, Olszewski JM, Saphos C, Visco DM, Hagmann WK (1997) Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. J Med Chem 40:1026-1040
42. 42. Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald PM, Cameron PM, Esser CK, Hagmann WK, Hermes JD, Springer JP (1995) Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci 4:1966-1976
43. 43. Browner MF, Smith WW, Castelhano AL (1995) Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry 34:6602-6610
44. 44. Li YC, Zhang X, Melton R, Ganu V, Gonnella NC (1998) Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Biochemistry 37:14048-14056
45. 45. Babine RE, Bender SL (1997) Molecular recognition of protein-ligand complexes: applications to drug design. Chem Rev 97:1359-1472
46. 46. Li J, Brick P, O'Hare MC, Skarzynski T, Lloyd LF, Curry VA, Clark IM, Bigg HF, Hazleman BL, Cawston TE, Blow DM (1995) Structure of full length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four bladed beta propeller. Structure 3:541-550
47. 47. Wood ND, Aitken M, Harris S, Kitchener S, McClelland GR Sharp S (1996) The tolerability and pharmacokinetics of the cartilage protective agent (Ro 32-3555) in healthy male volunteers. Br J Clin Pharmacol 42:676-677
48. 48. Finzel BC, Baldwin ET, Bryant GL Jr, Hess GF, Wilks JW, Trepod CM, Mott JE, Marshall VP, Petzold GL, Poorman RA, O'Sullivan TJ, Schostarez HJ, Mitchell MA (1998) Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity. Protein Sci 7:2118-2126
49. 49. Broadhurst MJ, Brown PA, Lawton G, Ballantyne N, Borkakoti N, Bottomley K, Cooper MI, Eatherton AJ, Kilford IR, Malsher PJ, Nixon JS, Lewis EJ, Sutton BM, Johnson WH (1997) Design and synthesis of the cartilage protective agent (CPA, Ro32-3555). Bioorg Med Chem Lett 7:2299-2302
50. 50. Beckett RP, Whittaker M (1998) Matrix metalloproteinase inhibitors. Exp Opin Ther Patents 8:259-282
51. 51. Glaxo Group Ltd. (1998) WO9748685 metalloprotease inhibitors. Exp Opin Ther Patents 8:1191-1194
52. 52. Whittaker M, Brown P (1998) Recent advances in matrix metalloproteinase inhibitor research and development. Curr Opin Drug Discov Dev 1:157-164
53. 53. Szardenings AK, Harris D, Lam S, Shi L, Tien D, Wang Y, Patel DV, Navre M, Campbell DA (1998) Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases. J Med Chem 41:2194-2200
54. 54. Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE (1999) Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. J Med Chem 42:87-94
55. 55. Pavlovsky AG, Williams MG, Ye Q-Z, Ortwine DF, Purchase CFII, White AD, Dhanaraj V, Roth BD, Johnson LL, Hupe D, Humblet C, Blundell TL (1999) X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci 8:1455-1462
56. 56. Bishop J, Greenham AK, Lewis EJ (1993) A novel in vivo model for the study of cartilage degradation. J Pharmacol Toxicol Methods 30:19-25
57. 57. Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewster M, Broadhurst MJ, Brown PA, Budd JM, Greenham AK, Johnson WH, Nixon JS, Rose F, Sutton B, Wilson K (1997) Ro32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 121: 540-546
58. 58. Wood ND, Aitken M, Durston S, Harris S, McClelland GR, Sharp S (1998) Cartilage Protective Agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. Agents Actions 49:49-55
59. 59. Blobel CP (1997) Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNFα and Notch. Cell 90:589-592
60. 60. Boasberg P, Harbaugh B, Roth B, et al (1996) Marimastat, a novel matrix metalloproetianse inhibitor in patients with hormone-refractory prostate cancer (abstract 671). Proc Am Soc Clin Oncol 15:258
61. 61. Hande K, Wilding G, Riple G, et al (1998) A phase I study of AG3340, a matrix metalloprotease inhibitor, in patients having advanced cancer (abstract). Ann Oncol 9 [Suppl 2]:74
62. 62. Hirte H, Goel R, Bennett K etal (1998) Phase I study of matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced cancer (abstract). Ann Oncol 9 [Suppl 2]:75
63. 63.Nicholls A, Bharadwaj R, Honig B (1993) Grasp-graphical representation and analysis of surface properties. Biophys J 64:166-169
64. 64. Gerber PR, Muller K (1995) MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. J Comput Aided Mol Des 9:251-268